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Introduction
Following the discovery of T helper 17 (Th17) cells in 2005,
considerable research efforts identified interleukin 17 (IL-17) and
Th17 responses as essential components of immunity to the
commensal fungus Candida albicans. Much less is understood
about regulatory T cells (Tregs) in candidiasis. However, emerging
data point towards a surprisingly complex relationship between
IL-17/Th17 and Treg responses during C. albicans infections,
wherein Tregs both suppress and enhance immunity. This review
will discuss the role of these responses during candidiasis and the
consequences for disease outcome and therapy.
IL-17/Th17 Responses Are Key Mediators of C.
albicans Antifungal Immunity
IL-17-mediated immunity is crucial for protection against C.
albicans infections, especially mucocutaneous infections, including
oral and dermal candidiasis (reviewed in [1]). ‘‘Experiments of
nature’’ have revealed mutations in humans that cause suscepti-
bility to chronic mucocutaneous candidiasis (CMC), nearly all of
which impact the IL-17/Th17 pathway (Table 1, reviewed in [2]).
For example, individuals with mutations in IL17RA, IL17RC, IL-
17F, or the IL-17 family–specific signaling molecule ACT1 suffer
from CMC [3,4] (Casanova and Puel, personal communication;
see Acknowledgments). CMC can be defined as a heterogeneous
group of disorders characterized by persistent or recurrent
Candida infection of mucosal membranes, skin, and nails. To
date, there is no animal model that fully recapitulates the complex
phenotype of CMC. However, models of oral and dermal
candidiasis are in agreement with human data. IL-23-/-, IL-
17RA-/-, IL-17RC-/-, and Act1-/- mice are susceptible to
oropharyngeal candidiasis (OPC) [5–7]. Similarly, IL-23-/- and
IL-17A-/- mice display susceptibility to dermal candidiasis [8].
Somewhat surprisingly, IL-17RA-/- and IL-23-/- mice are not
susceptible to vaginal candidiasis [9]. Although one study
demonstrated that pharmacological blockade of Th17 responses
increased vaginal fungal burdens, that study did not measure
markers of symptomatic infection [10]. Therefore, IL-17-mediated
immunity in candidiasis appears to be site dependent, though the
underlying basis for this tissue specificity is enigmatic.
C. albicans also causes disseminated infections, associated with
mortality rates of 50% or higher [11]. IL-17RA-/- and IL-17A-/-
mice show elevated susceptibility to disseminated candidiasis [12–
14]. However, humans with mutations in the IL-17 pathway
typically do not develop disseminated disease. One exception is
patients with CARD9 mutations, who display susceptibility to both
CMC and disseminated infection [15]. Why other IL-17 pathway
gene mutations do not predispose patients to heightened
susceptibility to disseminated candidiasis is unknown, although
the number of patients identified with such mutations is limited. It
is possible that under predisposing conditions (antibiotic treatment,
intravenous catheter use, or abdominal surgery), individuals with
impairments in the IL-17 pathway may be at increased risk for
disseminated candidiasis, an issue that will need to be monitored,
particularly considering the impending use of anti-IL-17 biologic
therapy for autoimmunity [16].
IL-17 Function and Sources
IL-17 exerts protective effects principally through the recruit-
ment and activation of neutrophils. IL-17 primarily acts upon
nonhematopoietic cells by stimulating the production of cytokines
and chemokines, such as granulocyte-colony stimulating factor (G-
CSF), interleukin 8 (IL-8) (humans), CXCL1, and CXCL5, which
serve to expand and recruit neutrophils [1]. Depletion of
neutrophils renders mice susceptible to OPC [17] and dissemi-
nated candidiasis [18]. Additionally, IL-17 signaling promotes
anti-Candida killing mechanisms such as production of antimi-
crobial peptides (e.g., salivary histatins, b-defensins, and S100A8/
9) [5,9,19].
CD4+ T cells are traditionally considered to be the primary
cellular source of IL-17 during mucosal C. albicans infections
[5,20]. This assumption is based on the observation that patients
with HIV/AIDS exhibit dramatically heightened susceptibility to
OPC [21]. Moreover, most Candida-specific memory T cells in
humans are Th17 cells. Similarly, in models of adaptive immunity,
Th17 and not Th1 cells are induced by Candida and are
protective against oral infections [20,22].
IL-17 is produced by both conventional Th17 cells and by
innate cells [23]. One recent report proposed a role for innate
lymphoid cell (ILC) production of IL-17 in host defense against
OPC [24]. However, IL-17 production by ILCs was not directly
demonstrated. Notably, Rag1-/- mice, which lack T cells but have
enriched numbers of ILCs, are highly susceptible to OPC [20,25],
raising questions about the relevance of ILCs in oral candidiasis.
Our recent data show that following immediate exposure to C.
albicans, oral IL-17 is produced not by ILCs but by cd-T cells and
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a subset of CD4+TCRb+ innate-like cells known as ‘‘natural’’
Th17 cells [26]. Whether one or all of these IL-17+ subsets are
necessary for host defense in humans remains to be determined.
Treg Cells: Regulators of Infectious Disease
Tregs are a distinct subset of CD4+ T cell whose primary
function is to restrict potentially pathogenic inflammatory immune
responses. Tregs possess an extensive armory of suppressive
mechanisms that can be cell contact dependent (acting through
inhibitory receptors such as cytotoxic T-lymphocyte-associated
protein 4 [CTLA-4]) or cell contact independent (acting via
inhibitory cytokines and generation of suppressive metabolites)
(reviewed in [27]). This suppressive tool kit makes Tregs adept at
controlling cell types from both the innate and adaptive arms of
the immune system. Several Treg subsets exist, including Tregs
expressing CD25 and the canonical Treg transcription factor
Foxp3 that will be the focus of this review. Foxp3+ Tregs can be
further divided into thymus-derived Tregs, which are fully
differentiated in the thymus, and peripherally derived (p)Tregs,
which differentiate from naı¨ve CD4+ T cells in the periphery
following antigen stimulation. Although a detailed description of
Treg biology is beyond the scope of this review, we refer the reader
to several excellent reviews for further information on this subject
[27,28].
It is now appreciated that Tregs contribute to immunity against
infectious pathogens. Inflammatory effector responses are critical
in host defense against pathogens. However, excessive inflamma-
tory responses can be damaging and therefore must be tightly
regulated. A beneficial role for Treg-mediated restraint of
immunopathology has been demonstrated in several viral and
parasitic infections [29,30]. In some settings, Tregs are also
required for long-term maintenance of protective immunity, for
example, in the context of Leishmania major infection [31].
Conversely, overly potent Treg suppression can inhibit protective
immunity, favoring the pathogen. A detrimental role for Treg
suppression has been demonstrated during Mycobacterium tuber-
culosis infection, in which depletion of Tregs resulted in enhanced
protective responses [32]. Tregs can also promote, rather than
prevent, inflammation. During mucosal herpes simplex virus
infections, Tregs promoted protective effector responses via
immune cell recruitment to sites of infection [33]. Therefore,
Tregs can have diverse impacts, depending on the infection.
IL-17/Th17 and Treg Responses Are Intricately
Linked during Candidiasis
Treg responses are elevated during C. albicans infections,
suggesting a functional role. An increase in the proportion of
CD4+CD25+ cells and expression of Foxp3 was detected in the
mesenteric lymph nodes (LNs) and stomachs of mice intragastri-
cally inoculated with C. albicans [34,35]. Similarly,
CD4+CD25+Foxp3+ cells expanded in mice systemically infected
with C. albicans [36]. However, Treg-mediated responses to C.
albicans, and indeed to other fungi, remain poorly understood.
Th17 and Treg subsets are reciprocally regulated during naı¨ve
T cell differentiation [37]. Reciprocal regulation of such responses
was observed in a model of gastrointestinal candidiasis, in which
increased Treg responses were associated with reduced Th17
responses and vice versa [34,35]. Conversely, Tregs can also
promote Th17 responses [37]. Accordingly, IL-17/Th17 and Treg
responses are positively associated during OPC and disseminated
candidiasis (Fig. 1). Treg depletion by anti-CD25 treatment results
in concurrent depletion of Th17 cells during OPC. In the same
model, co-transfer of CD4+CD25+ and CD4+CD25- cells into
Rag1-/- mice enhanced protective Th17 responses [25]. In
disseminated candidiasis, Tregs suppressed Th1 and Th2
responses while promoting Th17 responses in vitro [36].
Furthermore, Foxp3+ cell depletion in vivo was associated with
reduced IL-17/Th17 responses [36]. Notably, both studies
provide evidence that the mechanism of action is, at least in part,
through consumption of IL-2 by Tregs through the high affinity
IL-2R [25,36]. IL-2 is essential for Treg survival but limits Th17
differentiation [38]. Therefore, Treg consumption of IL-2 reduces
its local concentration, favoring Th17 development [25,36,39].
Whether IL-2 consumption by Tregs is a dominant mechanism for
driving IL-17 responses during candidiasis remains an open
question.
Plasticity is a phenomenon whereby CD4+ T cell subsets acquire
characteristics of other populations (reviewed in [40]). For
Table 1. Human genetic defects associated with susceptibility to Candida infections.
Gene Mutation Disease Phenotype Reference
DECTIN1 Autosomal recessive CMC [51]
CARD9 Autosomal recessive CMC and disseminated infection [15]
STAT3 Autosomal dominant Hyper IgE Syndrome [52,53]
TYK2 Autosomal recessive Hyper IgE Syndrome [54]
DOCK8 Autosomal recessive Hyper IgE Syndrome [55]
IL17RA Autosomal recessive CMC [3]
IL17F Autosomal dominant CMC [3]
ACT1 Autosomal recessive CMC [4]
STAT1 Autosomal dominant CMC [56,57]
IL12RB1 Autosomal recessive CMC [58]
AIRE Autosomal recessive APECED/APS1 [59,60]
CD25 Autosomal recessive Oral and esophageal candidiasis [45]
IL17RC Autosomal recessive CMC Casanova and Puel, personal communication
Adapted from references [1,2] and Casanova and Puel (personal communication). Abbreviations: APECED, autoimmune polyendocrinopathy-candidiasis-ectodermal
dystrophy; APS1, autoimmune polyendocrine syndrome type 1; IgE, immunoglobulin E.
doi:10.1371/journal.ppat.1004456.t001
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example, in some settings Tregs can express RORct and produce
IL-17A. Indeed, pTregs and Th17 cells possess an especially high
degree of phenotypic flexibility [40], which has been observed in
antifungal immunity. Specifically, dendritic cell recognition of b-
glucans in the Candida cell wall by dectin-1 promotes conversion
of Tregs to a RORct+IL-17A+ phenotype [41]. Moreover,
CD4+CD25+Foxp3+ cells isolated from systemically infected mice
expressed RORct and produced IL-17A, with the majority also
expressing pTreg markers [36]. Collectively, these studies indicate
that Tregs can promote IL-17/Th17 responses and acquire
characteristics of Th17 cells in response to C. albicans.
Final Outcome: Location, Location, Location
Although IL-17/Th17 and Treg responses can act cooperatively
during candidiasis, disease outcome is strikingly different depend-
ing on infection site. In OPC, Th17 enhancement by Tregs
increased resistance to infection [25]. In contrast, Treg enhance-
ment of Th17 responses in disseminated candidiasis was associated
with reduced resistance [36]. These studies suggest that inflam-
matory Th17 and Treg responses are protective at mucosal
surfaces but pathogenic in systemic candidiasis. Consistent with
this idea, humans with defective Th17 and Treg responses are
susceptible to CMC but not to disseminated candidiasis [42–45].
However, the concept that elevated Th17 and Treg responses are
harmful in disseminated candidiasis seemingly contrasts with the
apparent protective role of IL-17 in mice [12–14,36]. One
explanation is that these studies use knockout animals with
complete genetic ablation of IL-17 components and therefore do
not address the requirement of balanced immune responses. In
support of a pathogenic role for unbalanced Th17 and Treg
responses during candidiasis, cytokines associated with Th17
responses positively correlate with increasing disease severity in
disseminated candidiasis [46]. Similarly, overzealous Th17
responses are associated with immunopathology in gastrointestinal
candidiasis [47]. Furthermore, depletion of Tregs during dissem-
inated candidiasis increases resistance to disease [48]. Ultimately,
the balance between protective versus pathogenic immunity is
crucial in determining disease outcome.
How immune responses are shaped depends on factors in the
microenvironment. Commensal microbes ferment dietary fibers to
short chain fatty acids (SCFAs) that favor tolerogenic Tregs [49].
Additionally, transforming growth factor beta (TGFb) and retinoic
acid, which are enriched at the intestinal mucosa, promote Tregs
Figure 1. Treg/Th17 relationship during candidiasis. Tregs promote Th17 responses as well as acquire Th17 characteristics during disseminated
infection. However, Treg/Th17 responses are associated with pathogenicity in this form of candidiasis. Conversely, Treg enhancement of Th17
responses during OPC is protective. Tregs suppress Th17 responses during gastrointestinal candidiasis, leading to decreased C. albicans colonization.
Whether Tregs impact Th17 responses during vaginal and cutaneous candidiasis and the resulting outcome of disease remains to be determined.
doi:10.1371/journal.ppat.1004456.g001
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over Th17 responses [50]. Since C. albicans is a commensal of
human mucosae, it is likely that these tissues have evolved
tolerogenic mechanisms to live in harmony with this fungus. In
contrast, internal organs are shielded from the external environ-
ment and typically lack high levels of SCFAs and retinoic acid.
Therefore, inflammation induced during disseminated C. albicans
infection is more likely to go unchecked compared to mucosal
surfaces, resulting in collateral tissue damage. Overall, site-specific
factors are pivotal in dictating the balance between protective and
pathogenic Th17 and Treg responses.
Concluding Remarks
It is clear that IL-17/Th17 and Treg cells have a complex
relationship, exemplified during infections with C. albicans.
Although Th17 and Treg responses appear to be reciprocally
regulated in certain situations (e.g., gastrointestinal candidiasis),
Tregs promote Th17 activities and even acquire phenotypic
characteristics of Th17 cells in other settings (e.g., oral and
disseminated candidiasis). Notably, the impact of Th17 and Treg
responses on disease outcome is distinct in different forms of
candidiasis, highlighting the importance of microenvironment in
shaping overall immunity. Elucidating the factors that determine
the balance between protective versus pathogenic Th17 and Treg
responses during candidiasis will be an important future avenue of
research. Ultimately, it may be possible to exploit this information
in order to help tune appropriate responses in the context of
candidiasis.
Acknowledgments
We thank J-L Casanova and A. Puel for sharing unpublished information
(July 15, 2014; email communication to SLG).
References
1. Herna´ndez-Santos N, Gaffen SL (2012) Th17 cells in immunity to Candida
albicans. Cell Host Microbe 11: 425–435.
2. Huppler AR, Bishu S, Gaffen SL (2012) Mucocutaneous candidiasis: the IL-17
pathway and implications for targeted immunotherapy. Arthritis Res Ther 14: 217.
3. Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, et al. (2011) Chronic
mucocutaneous candidiasis in humans with inborn errors of interleukin-17
immunity. Science 332: 65–68.
4. Boisson B, Wang C, Pedergnana V, Wu L, Cypowyj S, et al. (2013) An ACT1
mutation selectively abolishes interleukin-17 responses in humans with chronic
mucocutaneous candidiasis. Immunity 39: 676–686.
5. Conti HR, Shen F, Nayyar N, Stocum E, Sun JN, et al. (2009) Th17 cells and
IL-17 receptor signaling are essential for mucosal host defense against oral
candidiasis. J Exp Med 206: 299–311.
6. Ho AW, Shen F, Conti HR, Patel N, Childs EE, et al. (2010) IL-17RC is
required for immune signaling via an extended SEF/IL-17R signaling domain in
the cytoplasmic tail. J Immunol 185: 1063–1070.
7. Ferreira MC, Whibley N, Mamo AJ, Siebenlist U, Chan YR, et al. (2014)
Interleukin-17-induced protein lipocalin 2 is dispensable for immunity to oral
candidiasis. Infect Immun 82: 1030–1035.
8. Kagami S, Rizzo HL, Kurtz SE, Miller LS, Blauvelt A (2010) IL-23 and IL-17A,
but not IL-12 and IL-22, are required for optimal skin host defense against
Candida albicans. J Immunol 185: 5453–5462.
9. Yano J, Kolls JK, Happel KI, Wormley F, Wozniak KL, et al. (2012) The acute
neutrophil response mediated by S100 alarmins during vaginal Candida
infections is independent of the Th17-pathway. PLoS ONE 7: e46311.
10. Pietrella D, Rachini A, Pines M, Pandey N, Mosci P, et al. (2011) Th17 cells and
IL-17 in protective immunity to vaginal candidiasis. PLoS ONE 6: e22770.
11. Pfaller MA, Diekema DJ (2010) Epidemiology of invasive mycoses in North
America. Crit Rev Microbiol 36: 1–53.
12. Huang W, Na L, Fidel PL, Schwarzenberger P (2004) Requirement of
interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect
Dis 190: 624–631.
13. Saijo S, Ikeda S, Yamabe K, Kakuta S, Ishigame H, et al. (2010) Dectin-2
recognition of alpha-mannans and induction of Th17 cell differentiation is
essential for host defense against Candida albicans. Immunity 32: 681–691.
14. van de Veerdonk FL, Kullberg BJ, Verschueren IC, Hendriks T, van der Meer
JW, et al. (2010) Differential effects of IL-17 pathway in disseminated candidiasis
and zymosan-induced multiple organ failure. Shock 34: 407–411.
15. Glocker EO, Hennigs A, Nabavi M, Schaffer AA, Woellner C, et al. (2009) A
homozygous CARD9 mutation in a family with susceptibility to fungal
infections. N Engl J Med 361: 1727–1735.
16. Miossec P, Kolls JK (2012) Targeting IL-17 and TH17 cells in chronic
inflammation. Nat Rev Drug Discov 11: 763–776.
17. Huppler AR, Conti HR, Hernandez-Santos N, Darville T, Biswas PS, et al.
(2014) Role of neutrophils in IL-17-dependent immunity to mucosal candidiasis.
J Immunol 192: 1745–1752.
18. Fulurija A, Ashman RB, Papadimitriou JM (1996) Neutrophil depletion
increases susceptibility to systemic and vaginal candidiasis in mice, and reveals
differences between brain and kidney in mechanisms of host resistance.
Microbiology 142: 3487–3496.
19. Conti HR, Baker O, Freeman AF, Jang WS, Holland SM, et al. (2011) New
mechanism of oral immunity to mucosal candidiasis in hyper-IgE syndrome.
Mucosal Immunol 4: 448–455.
20. Hernandez-Santos N, Huppler AR, Peterson AC, Khader SA, McKenna KC, et
al. (2013) Th17 cells confer long-term adaptive immunity to oral mucosal
Candida albicans infections. Mucosal Immunol 6: 900–910.
21. Glocker E, Grimbacher B (2010) Chronic mucocutaneous candidiasis and
congenital susceptibility to Candida. Curr Opin Allergy Clin Immunol 10: 542–
550.
22. Ba¨r E, Gladiator A, Bastidas S, Roschitzki B, Acha-Orbea H, et al. (2012) A
novel Th cell epitope of Candida albicans mediates protection from fungal
infection. J Immunol 188: 5636–5643.
23. Cua DJ, Tato CM (2010) Innate IL-17-producing cells: the sentinels of the
immune system. Nat Rev Immunol 10: 479–489.
24. Gladiator A, Wangler N, Trautwein-Weidner K, LeibundGut-Landmann S
(2013) Cutting edge: IL-17-secreting innate lymphoid cells are essential for host
defense against fungal infection. J Immunol 190: 521–525.
25. Pandiyan P, Conti HR, Zheng L, Peterson AC, Mathern DR, et al. (2011)
CD4(+)CD25(+)Foxp3(+) regulatory T cells promote Th17 cells in vitro and
enhance host resistance in mouse Candida albicans Th17 cell infection model.
Immunity 34: 422–434.
26. Conti HR, Peterson AC, Brane L, Huppler AR, Herna´ndez-Santos N, et al.
(2014) Oral-resident ‘natural’ Th17 cells and cd T cells control opportunistic
Candida albicans infections. J Exp Med. In press.
27. Vignali DA, Collison LW, Workman CJ (2008) How regulatory T cells work.
Nat Rev Immunol 8: 523–532.
28. Josefowicz SZ, Lu LF, Rudensky AY (2012) Regulatory T cells: mechanisms of
differentiation and function. Annu Rev Immunol 30: 531–564.
29. Fulton RB, Meyerholz DK, Varga SM (2010) Foxp3+ CD4 regulatory T cells
limit pulmonary immunopathology by modulating the CD8 T cell response
during respiratory syncytial virus infection. J Immunol 185: 2382–2392.
30. Hesse M, Piccirillo CA, Belkaid Y, Prufer J, Mentink-Kane M, et al. (2004) The
pathogenesis of schistosomiasis is controlled by cooperating IL-10-producing
innate effector and regulatory T cells. J Immunol 172: 3157–3166.
31. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL (2002) CD4+
CD25+ regulatory T cells control Leishmania major persistence and immunity.
Nature 420: 502–507.
32. Scott-Browne JP, Shafiani S, Tucker-Heard G, Ishida-Tsubota K, Fontenot JD,
et al. (2007) Expansion and function of Foxp3-expressing T regulatory cells
during tuberculosis. J Exp Med 204: 2159–2169.
33. Lund JM, Hsing L, Pham TT, Rudensky AY (2008) Coordination of early
protective immunity to viral infection by regulatory T cells. Science 320: 1220–
1224.
34. De Luca A, Montagnoli C, Zelante T, Bonifazi P, Bozza S, et al. (2007)
Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88,
and IDO-dependent inhibition of Rorc. J Immunol 179: 5999–6008.
35. Bonifazi P, Zelante T, D’Angelo C, De Luca A, Moretti S, et al. (2009)
Balancing inflammation and tolerance in vivo through dendritic cells by the
commensal Candida albicans. Mucosal Immunol 2: 362–374.
36. Whibley N, Maccallum DM, Vickers MA, Zafreen S, Waldmann H, et al. (2014)
Expansion of Foxp3(+) T-cell populations by Candida albicans enhances both
Th17-cell responses and fungal dissemination after intravenous challenge.
Eur J Immunol 44: 1069–1083.
37. Chen X, Oppenheim JJ (2014) Th17 cells and Tregs: unlikely allies. J Leukoc
Biol. In press.
38. Boyman O, Sprent J (2012) The role of interleukin-2 during homeostasis and
activation of the immune system. Nat Rev Immunol 12: 180–190.
39. Chen Y, Haines CJ, Gutcher I, Hochweller K, Blumenschein WM, et al. (2011)
Foxp3(+) regulatory T cells promote T helper 17 cell development in vivo
through regulation of interleukin-2. Immunity 34: 409–421.
40. Zhou L, Chong MM, Littman DR (2009) Plasticity of CD4+ T cell lineage
differentiation. Immunity 30: 646–655.
41. Osorio F, LeibundGut-Landmann S, Lochner M, Lahl K, Sparwasser T, et al.
(2008) DC activated via dectin-1 convert Treg into IL-17 producers.
Eur J Immunol 38: 3274–3281.
42. Milner JD, Holland SM (2013) The cup runneth over: lessons from the ever-
expanding pool of primary immunodeficiency diseases. Nat Rev Immunol 13:
635–648.
PLOS Pathogens | www.plospathogens.org 4 December 2014 | Volume 10 | Issue 12 | e1004456
43. Kekalainen E, Tuovinen H, Joensuu J, Gylling M, Franssila R, et al. (2007) A
defect of regulatory T cells in patients with autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy. J Immunol 178: 1208–1215.
44. Saito M, Nagasawa M, Takada H, Hara T, Tsuchiya S, et al. (2011) Defective
IL-10 signaling in hyper-IgE syndrome results in impaired generation of
tolerogenic dendritic cells and induced regulatory T cells. J Exp Med 208: 235–
249.
45. Sharfe N, Dadi HK, Shahar M, Roifman CM (1997) Human immune disorder
arising from mutation of the alpha chain of the interleukin-2 receptor. Proc Natl
Acad Sci U S A 94: 3168–3171.
46. MacCallum DM, Castillo L, Brown AJ, Gow NA, Odds FC (2009) Early-
expressed chemokines predict kidney immunopathology in experimental
disseminated Candida albicans infections. PLoS ONE 4: e6420.
47. Zelante T, De Luca A, Bonifazi P, Montagnoli C, Bozza S, et al. (2007) IL-23
and the Th17 pathway promote inflammation and impair antifungal immune
resistance. Eur J Immunol 37: 2695–2706.
48. Netea MG, Sutmuller R, Hermann C, Van der Graaf CA, Van der Meer JW, et
al. (2004) Toll-like receptor 2 suppresses immunity against Candida albicans
through induction of IL-10 and regulatory T cells. J Immunol 172: 3712–3718.
49. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, et al. (2013) The
microbial metabolites, short-chain fatty acids, regulate colonic Treg cell
homeostasis. Science 341: 569–573.
50. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, et al. (2007) Reciprocal
TH17 and regulatory T cell differentiation mediated by retinoic acid. Science
317: 256–260.
51. Ferwerda B, Ferwerda G, Plantinga TS, Willment JA, van Spriel AB, et al.
(2009) Human dectin-1 deficiency and mucocutaneous fungal infections.
N Engl J Med 361: 1760–1767.
52. Ma CS, Chew GY, Simpson N, Priyadarshi A, Wong M, et al. (2008) Deficiency
of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med
205: 1551–1557.
53. Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, et al. (2008)
Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-
IgE syndrome. Nature 452: 773–776.
54. Minegishi Y, Saito M, Morio T, Watanabe K, Agematsu K, et al. (2006) Human
tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals
involved in innate and acquired immunity. Immunity 25: 745–755.
55. Engelhardt KR, McGhee S, Winkler S, Sassi A, Woellner C, et al. (2009) Large
deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8)
in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol
124: 1289–1302.e1284.
56. Liu L, Okada S, Kong XF, Kreins AY, Cypowyj S, et al. (2011) Gain-of-function
human STAT1 mutations impair IL-17 immunity and underlie chronic
mucocutaneous candidiasis. J Exp Med 208: 1635–1648.
57. van de Veerdonk FL, Plantinga TS, Hoischen A, Smeekens SP, Joosten LA, et
al. (2011) STAT1 mutations in autosomal dominant chronic mucocutaneous
candidiasis. N Engl J Med 365: 54–61.
58. de Beaucoudrey L, Samarina A, Bustamante J, Cobat A, Boisson-Dupuis S, et al.
(2010) Revisiting human IL-12Rbeta1 deficiency: a survey of 141 patients from
30 countries. Medicine (Baltimore) 89: 381–402.
59. Kisand K, Boe Wolff AS, Podkrajsek KT, Tserel L, Link M, et al. (2010)
Chronic mucocutaneous candidiasis in APECED or thymoma patients
correlates with autoimmunity to Th17-associated cytokines. J Exp Med 207:
299–308.
60. Puel A, Doffinger R, Natividad A, Chrabieh M, Barcenas-Morales G, et al.
(2010) Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with
chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome
type I. J Exp Med 207: 291–297.
PLOS Pathogens | www.plospathogens.org 5 December 2014 | Volume 10 | Issue 12 | e1004456
